Skip to main content
U.S. Department of Energy
Office of Scientific and Technical Information

Comparison of fluorine-18-2-fluorodeoxyglucose and gallium-67 citrate imaging for detection of lymphoma

Journal Article · · J. Nucl. Med.; (United States)
OSTI ID:6593133
Patients with lymphomas are conventionally imaged with (/sup 67/Ga)citrate for tumor detection and determination of dissemination. Fluorine-18-2-fluoro-2-deoxy-D-glucose (( /sup 18/F)FDG) is a radiopharmaceutical that accumulates into tissues where glucose utilization is enhanced, such as tumors. Six cancer patients (five non-Hodgkin's lymphomas, one endodermal retroperitoneal sinus carcinoma) were imaged with (/sup 18/F)FDG and (/sup 67/Ga)citrate whole-body scintigraphies in order to compare the sensitivities of these two tumor imaging radiopharmaceuticals. Among the five untreated lymphoma patients, two /sup 67/Ga scans and four (/sup 18/F)FDG scans were positive; in the patient with the retroperitoneal carcinoma who had a positive (/sup 18/F)FDG scan before treatment, both scans were negative after treatment. Fluorine-18 FDG may be a more sensitive tumor-detecting radiopharmaceutical for non-Hodgkin's lymphoma than (/sup 67/Ga)citrate.
Research Organization:
Turku Univ. Central Hospital, Finland
OSTI ID:
6593133
Journal Information:
J. Nucl. Med.; (United States), Journal Name: J. Nucl. Med.; (United States) Vol. 3; ISSN JNMEA
Country of Publication:
United States
Language:
English